Holen Sie sich die Stockscreener-App
6.76
2.45%
-0.17
Handel nachbörslich:
6.79
0.03
+0.44%
Nuvation Bio Inc Aktie (NUVB) Neueste Nachrichten
Nuvation Bio | 4: Statement of changes in beneficial ownership of securities-Officer Hattersley Gary - Moomoo
Nuvation Bio (NUVB) CSO sells 100K shares at $7.09 - Stock Titan
Why is Nuvation Bio stock rallying today? By Investing.com - Investing.com Canada
Nuvation Bio stock rises after Cantor starts at Overweight - Investing.com
Nuvation Bio rises as Cantor initiates at overweight - Seeking Alpha
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating By Investing.com - Investing.com India
JPMorgan sees 100% upside in overlooked cancer drug stock - thestreet.com
FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma - AllSci
Nuvation Bio receives FDA fast track status for brain cancer drug - Investing.com South Africa
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma - PR Newswire
Market Sentiment Around Loss-Making Nuvation Bio Inc. (NYSE:NUVB) - Moomoo
One NYSEListed Biotechnology Stock at Resistance Level – NUVB - kalkine.ca
Nuvation (NUVB) Results Breakdown: EPS Comes in Above Forecast for the Current Session; Share Response - Vinanet
Nuvation Bio (NUVB) Institutional Ownership 2026 - MarketBeat
This cancer drug stock could double as its treatment hits the market, JPMorgan says - CNBC
Nuvation wins new Overweight at J.P. Morgan (NUVB:NYSE) - Seeking Alpha
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know - Yahoo Finance
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits
JPMorgan Initiates Nuvation Bio at Overweight With $13 Price Target - marketscreener.com
JPMorgan initiates Nuvation Bio stock coverage with overweight rating By Investing.com - Investing.com South Africa
JPMorgan initiates Nuvation Bio stock coverage with overweight rating - Investing.com
The Manufacturers Life Insurance Company Reduces Stake in Nuvation Bio Inc. $NUVB - marketbeat.com
Nuvation Bio (NUVB) Is Down 5.8% After Wider Q2 Loss Despite Surging Revenue And IBTROZI Focus - simplywall.st
Nuvation Bio (NUVB) Q2 2026 Earnings Call Transcript - The Globe and Mail
Nuvation Bio (NUVB) Could Be 69% Undervalued On Earnings And IBTROZI Data Focus - Sahm
Brokers Set Expectations for Nuvation Bio FY2026 Earnings - MarketBeat
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
559,180 Shares in Nuvation Bio Inc. $NUVB Bought by Renaissance Technologies LLC - marketbeat.com
Power Solutions International And 2 More Growth Stocks With Strong Insider Ownership - simplywall.st
HC Wainwright Predicts Nuvation Bio Q1 Earnings - MarketBeat
Nuvation Bio Q2 Earnings Call Highlights - marketbeat.com
Nuvation Bio Inc (NUVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
A Quick Look at Today's Ratings for Nuvation Bio(NUVB.US), With a Forecast Between $12 to $21 - moomoo.com
Truist Financial Maintains Nuvation Bio(NUVB.US) With Buy Rating, Announces Target Price $13 - Moomoo
RBC Adjusts PT on Nuvation Bio to $20 From $19, Maintains Outperform Speculative Risk Rating - marketscreener.com
Why Nuvation Bio (NUVB) Is Down 8.8% After Surging Q2 2026 Revenue and IBTROZI Data Tease - simplywall.st
NUVB SWOT Analysis: Revenue Surge Amidst Ongoing Losses Revealed in 10-Q Filing - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc - The National Law Review
Earnings call transcript: Nuvation Bio tops revenue forecasts in Q2 2026 - Investing.com Nigeria
Nuvation Bio (NYSE:NUVB) Announces Quarterly Earnings Results - MarketBeat
Nuvation Bio Inc. Stock 12‑Month Price Target Raised to $12.89, Implies 102% Upside - TradingView
Nuvation Bio earnings missed by $0.03, revenue topped estimates - Investing.com
Nuvation Bio Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Nuvation Bio reports Q2 revenue of $31.7 million - Investing.com
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Nuvation Bio Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (NUVB) Nuvation Bio Posts Q2 Net Loss of $0.18 per Share, vs. FactSet Est of $0.15 Loss - marketscreener.com
Earnings Flash (NUVB) Nuvation Bio Inc. Reports Q2 Revenue $31.7M, vs. FactSet Est of $27.0M - marketscreener.com
Nuvation Bio posts $31.7M Q2 revenue, $23.2M IBTROZI product sales and $62.8M net loss - TradingView
BRIEF-Nuvation Bio Q2 EPS USD -0.18 - TradingView
Nuvation Bio (NYSE: NUVB) posts $31.7M Q2 revenue and $62.8M loss - Stock Titan
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - TradingView
Nuvation Bio Inc. Q2 2026: Revenue $31.7M, EPS $(0.18) — 10-Q Summary - TradingView
Nuvation Bio (NUVB) surges to $114.9M revenue and issues $250M notes - stocktitan.net
Nuvation Bio Inc. (NUVB) options chain - Yahoo Finance Australia
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
Nuvation Bio earnings on deck: IBTROZI launch faces test By Investing.com - Investing.com Nigeria
Nuvation Bio earnings on deck: IBTROZI launch faces test - Investing.com
Nuvation Bio to present subgroup analyses at lung cancer conferences - Investing.com
Do IBTROZI’s TRUST Data Shape Nuvation Bio’s (NUVB) Edge in Targeted Lung Cancer Therapy? - Yahoo Finance
Nuvation Bio to present subgroup analyses at lung cancer conferences By Investing.com - Investing.com Nigeria
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses - PR Newswire
Nuvation Bio will present IBTROZI data across lung cancer subgroups - Stock Titan
Arrowstreet Capital Limited Partnership Has $6.17 Million Stake in Nuvation Bio Inc. $NUVB - MarketBeat
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):